The latest news on life science tools and technology in genetics, genomics, and molecular diagnostics.
The company provided updates on its newborn screening testing presence.
The firm provided updates on its bacterial pathogen detection and antimicrobial resistance testing for bacterial isolates and a direct-from-urine test.
The system is designed to analyze data from routine blood and biochemistry tests to identify immunological abnormalities that indicate high cancer risk.
Agilent has partnered with the National University of Singapore and National University Hospital to establish the S$38 million ($27.4 million) research and development facility in Singapore.
Canaccord Genuity began coverage of Castle Biosciences with a Buy rating and a $26 price target, while SVB Leerink assigned an Outperform rating and a $28 price target.
